Breathe Well Live Well
Condition: Asthma
Interventions: Drug: Fluticasone furoate (FF) Dry Powder Inhaler; Drug: Fluticasone propionate (FP) Dry Powder Inhaler; Drug: Budesonide (BUD) Turbuhaler; Drug: Placebo (ELLIPTA or DISKUS)
Sponsor: GlaxoSmithKline
Not yet recruiting – verified December 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Device: Wright Nebulizer; Device: Aerogen Solo Nebulizer; Drug: Methacholine Chloride
Sponsor: University of Saskatchewan
Recruiting – verified November 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
Condition: Asthma
Interventions: Drug: Methacholine Chloride; Device: Wright nebulizer; Device: Bennett-Twin nebulizer; Device: Aeroneb Solo
Sponsor: University of Saskatchewan
Recruiting – verified June 2016
View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days
 |
Related Articles |
Persistent nasal symptoms and mediator release after continuous pollen exposure in an environmental challenge chamber.
Ann Allergy Asthma Immunol. 2016 Jun 1;
Authors: Okuma Y, Okamoto Y, Yonekura S, Iinuma T, Sakurai T, Hamasaki S, Ohki Y, Yamamoto H, Sakurai D
Abstract
BACKGROUND: Immediate- and late-phase reactions are associated with nasal symptoms of patients with allergic rhinitis.
OBJECTIVE: To examine the symptoms and mediators released after continuous allergen exposure in an environmental challenge chamber (ECC).
METHODS: Fifteen patients with Japanese cedar pollinosis were enrolled in this study and continuously exposed to cedar pollen at a concentration of 8,000 grains/m(3) for 3 hours in an ECC. Nasal function tests were performed, and nasal secretions were collected before pollen exposure (0 hour), immediately after exiting the ECC (3 hours), and 6 hours after exiting the ECC (9 hours). Symptom scores were recorded every 30 minutes in the ECC and every 3 hours after exiting the ECC. The frequency of sneezing and nose blowing also was monitored.
RESULTS: The severity of symptoms in the ECC peaked approximately 2 hours after the beginning of pollen exposure and continued more than 6 hours after leaving the ECC. Concentrations of histamine, tryptase, interleukins 5, 3, 33, and 31, and substance P increased over time, whereas that of nasal fractional exhaled nitric oxide decreased.
CONCLUSION: Various mediators are released during continuous allergen exposure, which subsequently induce persistent nasal symptoms. Effective treatment is required to control the intense inflammation observed after allergen exposure.
PMID: 27263086 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
| Related Articles |
Hypoxic Challenge Testing for Fitness to Fly with Severe Asthma.
Aerosp Med Hum Perform. 2016;87(6):571-574
Authors: George PM, Orton C, Ward S, Menzies-Gow A, Hull JH
Abstract
INTRODUCTION: Commercial airline travel poses a recognized risk to patients with respiratory disease, including in those with asthma. Hypoxic challenge testing (HCT) is typically employed to mitigate this risk by dictating in-flight oxygen requirement.
METHODS: The role of HCT has not been formally studied in patients with severe asthma and we therefore evaluated HCT assessment in a cohort of patients with severe asthma (N = 37).
RESULTS: Over half (57%) of patients had a positive HCT. Baseline oxygen saturation (Spo2) was poorly predictive of a recommendation for supplementary oxygen in flight; two-thirds of those deemed to require oxygen had a baseline Spo2 > 95%. A combination of any two of: Pao2 ? 10.5 kPa, FEV1 ? 60% predicted, and PEF ? 350 L · min(-1) predicted the need for in-flight oxygen with a sensitivity of 89% and a specificity of 69%. Furthermore, no patient with an Spo2 > 95% and FEV1 > 85% predicted had a positive HCT.
CONCLUSION: Overall, the findings indicate that HCT should be considered for all patients with severe asthma, regardless of resting oxygen saturation level. George PM, Orton C, Ward S, Menzies-Gow A, Hull JH. Hypoxic challenge testing for fitness to fly with severe asthma. Aerosp Med Hum Perform. 2016; 87(6):571-574.
PMID: 27208681 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
|
The challenge of asthma
Inquirer.net Asthma is a chronic respiratory disease that affects over 300 million people worldwide. Of the 11 million reported cases in the Philippines, it is prevalent among patients under 40 years old, especially children. The bigger challenge is that lack of … |
View full post on asthma – Google News
Conditions: Asthma; Rhinovirus; Picornaviridae Infections; Common Cold
Interventions: Drug: OC459; Drug: Placebo; Other: Rhinovirus
Sponsors: Imperial College London; Medical Research Council; Atopix Therapeutics, Ltd.
Recruiting – verified January 2016
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: CRD007; Other: Placebo
Sponsor: RSPR Pharma AB
Completed – verified November 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
Small Interfering RNA Against CD86 During Allergen Challenge Blocks …
Medscape Methods We investigated the effects of the downregulation of CD86 by short interfering RNAs (siRNAs) on Th2 cytokine production in the effector phase in vitro and on asthma phenotypes in ovalbumin (OVA)-sensitized and -challenged mice. |
View full post on asthma – Google News
NPR (blog) |
Johns Hopkins experts challenge belief that city living raises asthma risk
The Hub at Johns Hopkins Challenging the long-standing belief that city dwellers suffer disproportionately from asthma, the results of a new Johns Hopkins Children's Center study of more than 23,000 U.S. children reveal that income, race, and ethnic origin may play far more … The City Might Not Be To Blame For High Asthma Rates Study Questions Link Between Asthma and City Living Researchers debunk the idea that asthma is more common in inner cities |
View full post on asthma – Google News